[18F]AlF-FAP-NUR用于PET显像癌症相关成纤维细胞的临床前评价与首次人体研究
本研究自动化制备[18F]AlF-FAP-NUR(45分钟内,未衰变校正放射化学产率18.73±4.25%,n=3),在HT1080-FAP细胞中较[68Ga]Ga-FAP-2286摄取和内化更快更高、外排更低;荷瘤小鼠micro-PET示分布模式相似但肿瘤特异性摄取更高、靶本比改善;患者原发肿瘤显着摄取,膀胱高摄取提示经尿排泄。
要点
- [18F]AlF-FAP-NUR自动化制备45分钟,未衰变校正放射化学产率18.73±4.25%(n=3)。
- 细胞研究示较[68Ga]Ga-FAP-2286摄取和内化更快更高、外排更低。
- 荷瘤小鼠micro-PET示分布模式相似但肿瘤特异性摄取更高、靶本比改善。
核心结论
- 基于[18F]F的物理显像特性与较长半衰期,[18F]AlF-FAP-NUR表现出肿瘤特异性蓄积增强和靶本比升高等有前景的特性,使其成为可进一步临床研究的候选者。
研究设计与样本
- 临床前细胞与动物研究及首次人体显像研究;细胞用HT1080-FAP细胞,动物用荷瘤小鼠模型,并纳入患者行PET显像;试验 retrospectively registered 于2023年10月25日(ChiCTR2300076976)。
主要发现
- [18F]AlF-FAP-NUR自动化制备45分钟,未衰变校正放射化学产率18.73±4.25%(n=3)。
- 在HT1080-FAP细胞中,较[68Ga]Ga-FAP-2286,[18F]F标记肽示细胞摄取和内化更快更高、细胞外排更低。
- 荷瘤小鼠micro-PET与生物分布研究示两种示踪剂分布模式相似,但[18F]AlF-FAP-NUR肿瘤特异性摄取显着更高,靶本比改善。
- 患者原发肿瘤中见[18F]AlF-FAP-NUR显着蓄积,膀胱高摄取提示主要经尿排泄。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibroblast activation protein (FAP) has gained attention as a promising molecular target with potential utility for cancer diagnosis and therapy. [68Ga]Ga-labeled FAP-targeting peptides have been successfully applied to positron emission tomography (PET) imaging of various tumor types. To meet the applicable demand for peptide-based FAP tracers with high patient throughput, we herein report the radiosynthesis, preclinical evaluation, and the first-in-human imaging of a novel [18F]F-labeled FAP-targeting peptide. RESULTS: [18F]AlF-FAP-NUR was automatedly prepared within 45 min with a non-decay corrected radiochemical yield of 18.73 ± 4.25% (n = 3). Compared to [68Ga]Ga-FAP-2286, the [18F]F-labeled peptide demonstrated more rapid, higher levels of cellular uptake and internalization, and lower levels of cellular efflux in HT1080-FAP cells. Micro-PET imaging and biodistribution studies conducted on xenograft mice models revealed a similar distribution pattern between the two tracers. However, [18F]AlF-FAP-NUR demonstrated significantly higher tumor-specific uptake resulting in improved Tumor-Background Ratios (TBRs). In the patients, a significant accumulation of [18F]AlF-FAP-NUR was found in the primary tumor. High uptake of the tracer within the bladder indicated that its major route of excretion was through urine. CONCLUSIONS: Based on the physical imaging properties and longer half-life of [18F]F, [18F]AlF-FAP-NUR exhibited promising characteristics such as enhanced tumor-specific accumulation and elevated TBRs, which made it a viable candidate for further clinical investigation. TRIAL REGISTRATION: www.Chictr.org.cn , ChiCTR2300076976 Retrospectively registered 25 October 2023. at, URL: https://www.chictr.org.cn/showproj.html?proj=206753 .
引用
- Liu S, Zhang Z, Zhong J, et al. Preclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts. EJNMMI Res. 2024. PMID: 39352615. doi:10.1186/s13550-024-01139-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。